Principles of Educational Outreach ('Academic Detailing') to Improve Clinical Decision Making
Stephen B. Soumerai, ScD, Jerry Avorn, MD With the efficacy and costs of medications rising rapidly, it is increasingly important to ensure that drugs be prescribed as rationally as possible. Yet, physicians' choices of drugs frequently fall short of the ideal of precise and cost\x=req-\ effective decision making. Evidence indicates that such decisions can be improved in a variety of ways. A number of theories and principles of communication and behavior change can be found that underlie the success of pharmaceutical manufacturers in influencing prescribing practices. Based on this behavioral science and several field trials, it is possible to define the theory and practice of methods to improve physicians' clinical decision making to enhance the quality and cost-effectiveness of care. Some of the most important techniques of such "academic detailing" include (1) conducting interviews to investigate baseline knowledge and motivations for current prescribing patterns, (2) focusing programs on specific categories of physicians as well as on their opinion leaders, (3) defining clear educational and behavioral objectives, (4) establishing credibility through a respected organizational identity, referencing authoritative and unbiased sources of information, and presenting both sides of controversial issues, (5) stimulating active physician participation in educational interactions, (6) using concise graphic educational materials, (7) highlighting and repeating the essential messages, and (8) providing positive reinforcement of improved practices in follow-up visits. Used by the nonprofit sector, the above techniques have been shown to reduce inappropriate prescribing as well as unnecessary health care expenditures. (JAMA. 1990 ;263:549-556) THE HIGH cost of medical care and increasing concern about appropriate use of medical technology have resulted in a new wave of interest in how physi¬ cians can be encouraged to make more accurate and cost-effective clinical deci-sions. Some efforts have emphasized re¬ strictions and economic disincentives, but evidence is emerging that in some applications such strategies may threat¬ en the quality of care at least as much as they reduce expenditures.1,2 Continuing education has received much less atten¬ tion as a means of behavior change, per¬ haps because it often is ineffective in this regard. 3 University-based educational out-reach (sometimes known as "public in¬ terest detailing" or "academic detail¬ ing") is a newer approach that has been evaluated as part of a four-state ran¬ domized, controlled trial. 4"7 Prescribing problems that could be targeted by such approaches include use of drugs with low benefit/risk ratios when safer alter¬ natives are available, use of ineffective or marginal therapies for treatable con¬ ditions, use of excessive numbers of medications in vulnerable populations (eg, children and the elderly), use of high-cost agents when less expensive medications would work as well, and underuse of effective agents for major illnesses (eg, hypertension in the elder¬ ly).5 In one study of educational out¬ reach, two brief visits to physicians by clinical pharmacists trained in effective techniques of communication and per¬ suasion as well as pharmacotherapy were found to reduce inappropriate pre¬ scribing of cerebral vasodilators, cephalexin, and propoxyphene by 14% in com¬ parison with controls (P=.0001).4 A formal economic analysis of these find¬ ings estimated benefits (reductions in unnecessary expenditures) and costs board certification, and specialty did not affect response to the educational intervention, a second reinforcement visit substantially increased compliance with prescribing recommendations.
Other controlled studies also have docu¬ mented the effectiveness and receptiv¬ ity of physicians to face-to-face counsel¬ ing.5,8"10 This article discusses the principles and techniques of such ap¬ proaches to physician behavior change.
The prescribing of drugs has served as a useful model for studying ways of improving the accuracy of physician de¬ cision making. Problems of misutilization of drugs stem from many sources, only some ofwhich relate to the pharma¬ ceutical industry.5 Nonetheless, the in¬ dustry's marketing strategies may serve as an instructive model (both good and bad) for those interested in improv¬ ing the rationality of clinical decision making. Detailing, the promotional ac¬ tivities of pharmaceutical company sales representatives, accounted for more than half of the estimated $3 bil¬ lion spent annually on promotion by US pharmaceutical companies in the early 1980s (Wall Street Journal. May 25, 1984:31, 49 25, 1984:31, 49) .n"13 The detailer/physician ratio is even higher in some other western countries, approxi¬ mating 1:3 in Brazil and 1:4 in Mexico.14 One form of evidence for the effec¬ tiveness of these traveling personnel is that pharmaceutical companies contin¬ ue to invest such large sums of money in this approach, based on their own costbenefit calculations. Several studies in¬ dicate that for many physicians, the detailer is generally the first source of information about new therapies.15 In¬ deed, even when commercial messages on product efficacy differ markedly from objective, scientific sources of in¬ formation, the beliefs concerning sever¬ al drugs of a large, randomly selected sample of primary care physicians cor¬ responded more closely to the commer¬ cial information. 16 Despite the fact that detailers shape so much prescribing be¬ havior, there is little in the scientific literature about the techniques or ap¬ proach of these representatives and how they might be adapted to reduce inappropriate prescribing. The few studies that do exist14,17 simply describe the broadly defined components of sales presentations, as derived from survey information.
The following analysis of common techniques and principles employed by such change-agents are based on indepth interviews with and videotapes of former pharmaceutical representa¬ tives, other written accounts of the de¬ tailing process, and our own experience in mounting several trials of "public in¬ terest detailing" in five states to reduce excessive or inappropriate prescrib¬ ing.4"710 As discussed below, these tech¬ niques are also based on research in the fields of adult learning, diffusion ofinno¬ vations, and persuasive communica¬ tion.
BEHAVIOR CHANGE STRATEGIES
The effectiveness of the commercial detail visit is the result ofmore than 100 years of sales experience. Generally lasting less than 10 minutes, the presen¬ tation is likely to contain several effec¬ tive strategies for behavior change that serve to reinforce and complement one another.1819 Some similarities exist be¬ tween pharmaceutical marketing goals and several objectives of nonprofit or¬ ganizations. For example, clinical de¬ partment chairpersons, quality assur¬ ance staff, and health care administra¬ tors and payers would like to encourage prescribing behavior that would contain costs without sacrificing quality of care and, ideally, would improve it. In previ¬ ous studies the use of inexpensive but effective antibiotics has been promoted to replace costly cephalosporins in the treatment of uncomplicated infec¬ tions4,6 , 7, 9; the use of potentially danger¬ ous antibiotics to treat minor infections in ambulatory practice has been cur¬ tailed (eg, chloramphenicol for viral up¬ per respiratory tract infections)9; and safe and effective over-the-counter an¬ algesics, such as aspirin, have been sub¬ stituted for less effective and potential¬ ly problematic prescription drugs such as propoxyphene.6 Other interventions have focused on the way a drug is pre¬ scribed; for example, certain effective drugs are prescribed too frequently or in excessive dosages, causing unneces¬ sary risks of adverse drug reactions and increased costs.20,21 While important dif¬ ferences exist between pharmaceutical marketing and medical education or quality assurance, there is reason to be¬ lieve that many of the techniques de¬ scribed below could be adapted to such purposes. Our goal is to identify those aspects of detailing that can be put in the service of supporting the physician in making better therapeutic decisions, while leaving aside any techniques that might be manipulative or serve only to increase sales of a given product.
Defining Specific Problems and Objectives
A key first step in any program to influence clinical decision making is to define the area(s) to be addressed and the specific behaviors to be encouraged or discouraged. Such agenda setting is more straightforward in the pharma¬ ceutical industry, where the fiscal "bot¬ tom line" is, by definition, the outcome of concern and increasing sales of specif¬ ic branded products is the means toward that end. Sponsors of other progams face more complicated choices. For a nonprofit health maintenance organiza¬ tion, employer, or insurer responsible for all aspects of medical care, the out¬ come of concern may be the highest pos¬ sible quality of care at the lowest possi¬ ble cost-goals that may conflict and that often cut across multiple categories of service (eg, drugs, hospitalization, and physician visits may all be affected by use of histamine antagonists). It therefore is necessary to begin by iden¬ tifying the specific cases of practice that are of highest concern in terms of quali¬ ty and/or cost and to design a program that will target these decisions initially, specifying clear alternatives to be en¬ couraged. For example, Ray et al22 used Medicaid claims data to identify inap¬ propriate prescribing of tetracycline to children by general practitioners in Tennessee. Subsequent educational ef¬ forts focused on the objectives of reduc¬ ing this practice as much as possible among targeted groups due to the risk of permanent discoloration of develop¬ ing teeth and substituting safer antibi¬ otics for this population. A secondary (but less measurable) objective was to reduce prescribing of any antibiotics for simple upper respiratory tract infec¬ tions.
Market Research
One of the most important lessons that can be derived from pharmaceuti¬ cal marketing strategy is the need to understand the motivations that under¬ lie physician use of a particular product. One failure of traditional continuing medical education has been the assump¬ tion that the transmittal of rational in¬ formation alone, independent of how it is provided, will predictably result in improved clinical decisions.3 While the provision of new knowledge and infor¬ mation may be sufficient in some cases, considerable research has made appar¬ ent the need to consider other "nonscientific" factors such as attitudes toward particular diseases or patients, habits, peer influence, patient demand, time constraints in busy office practices, and economic incentives as prerequisites to the design of educational messages.523"26 For example, providing more informa¬ tion on the therapeutic efficacy of aspi¬ rin may be irrelevant to the physician who prescribes prescription analgesics primarily in response to patient de¬ mands.
Several approaches can be used to determine physician motivations for their therapeutic decisions, including focus group interviews, surveys of prescribers, and ongoing communication between detailers/educators and physi¬ cians. In focus group interviews,26 the market researcher assembles a small group of consumers (in this case, physi¬ cians) and attempts to stimulate a frank and open discussion of the important motivations for choosing particular products over others. On one level, an attempt is made to identify the major product characteristics (eg, efficacy or safety) that physicians value in their choice of similar products as well as phy¬ sician perceptions of the comparative advantages and disadvantages of rec¬ ommended vs competitive products. These factors eventually became major messages to communicate in face-toface details and printed advertisements (eg, the relative efficacy of one product over another, patient convenience, side effects profile, and so on).
If the facilitator is sufficiently skilled, he or she may discover some key nonclinical motivations that might other¬ wise remain hidden owing to their nega¬ tive social or ethical tint (eg, prescribing tranquilizers to quiet demented elderly patients at the request of nursing home staff). Practice-driven motivations may cause many physicians, although fully aware of the pharmacology involved, to use marginal therapies because of pa¬ tient demand factors or intentional use of active placebos.23 For this sizable group, an intervention aimed only at presenting efficacy data would yield minimal results. In our prior work, we instead developed a set of "patient man¬ agement strategies" and education di¬ rected at the patient (Fig 1) to help these physicians to cope better with in¬ appropriate requests.
The focus group approach may fail if the group of physician-volunteers (or paid consultants) sampled is not generalizable to the larger group of practitio¬ ners. To avoid this problem, several such groups are convened and larger, structured or unstructured surveys of more representative samples of target physicians are conducted before devel¬ opment of program content. Thus, fit¬ ting the relevant information to the val¬ ues, attitudes, and beliefs of practicing physicians is an ongoing task both in defining the general content of commu¬ nications in the planning stage and in the process of one-on-one education.
Establishing Credibility
Establishing and maintaining a credi¬ ble identity is an essential ingredient in effective communication. In the phar¬ maceutical industry, credibility is sought by reference to prestigious clini¬ cal research centers that evaluated the drug and journals that reported the re¬ search. According to representatives we interviewed, the "aura" surrounding identification with clinical trials at such research centers may contribute as much to adoption of the drug as the scientific aspects of the studies. Phar¬ maceutical companies also sponsor sci¬ entific symposia for practicing physi¬ cians to convey product-specific in¬ formation and to enhance the academic image of the company and its represen¬ tatives, although data suggest that the content of such symposia occasionally may be colored by product sales mes-sages.27,28 Physician awareness of the profit motive and its potential impact on the objectivity of promotional messages presents a formidable obstacle for com¬ mercial representatives.
Sponsorship of educational outreach programs by neutral professional groups represents a significant advan¬ tage for "nonprofit" detailers. Two tri¬ als of face-to-face prescribing education utilized the imprimatur of respected medical organizations, a state medical society and a medical school drug infor¬ mation program.4,9 Such unbiased orga¬ nizational identities were an important factor in achieving high rates of physi¬ cian acceptance of the personal visits (92% of physicians randomized to this group agreed to meet with the medical school-based "detailer").4 Another im¬ portant aspect of both programs was their utilization of academically based educators bringing the latest clinical findings of importance to the physician's doorstep. In another setting, the teach¬ ing hospital, credibility also can be dem¬ onstrated through identification with expert consultants (eg, antibiotic use guidelines approved by the infectious disease service).20 Targeting 'High-Potential' Physicians Pharmaceutical sales representa¬ tives often prioritize their sales calls in relation to the magnitude of potential sales to individual physicians.29 These determinations are made through com¬ pany profiles of physicians' previous prescribing patterns and other data on physician specialties and interests. Thus, a representative can maximize his potential sales per hour of effort by spending the most time with physicians whose total prescribing volumes are high enough to yield potentially high sales of the detailer's products or with physicians who are opinion leaders. Similarly, from a noncommercial stand¬ point, it makes no economic sense to blanket all physicians with face-to-face interventions when many of these phy¬ sicians do not prescribe either inappro¬ priately or in high enough volumes to yield substantial savings or improve¬ ments in care.
In previous controlled studies of uni¬ versity-based pharmaceutical educa¬ tion for community physicians,4,6,7 9 mod¬ erateto high-volume prescribers of target drugs were identified using data from the Medicaid Management Infor¬ mation Systems in five states. While physicians reduced excessive prescrib¬ ing to the same degree regardless of baseline levels of use, the benefit/cost ratio was the highest (approximately 3:1) in the group with the highest initial volume of target drug use.6 As hospi¬ tals, health maintenance organizations, and other health care organizations con¬ tinue to develop computerized systems to track resource utilization on a physi¬ cian-specific basis, it will become increasingly practical to identify physi¬ cians with particular utilization prob¬ lems and present them with focused educational interventions. However, in the above studies these data were not used on an individual basis to feed back information indicating that particular physicians were operating outside of es¬ tablished norms. Surveillance and feed¬ back of this sort is another approach that may work best in certain settings with established lines of authority (eg, teaching hospitals and staff model health maintenance organizations).
Involvement of 'Opinion Leaders'
A key pharmaceutical marketing strategy is to identify and involve local physician opinion leaders: those individ¬ uals who tend to be early adopters of pharmaceutical innovations and impor¬ tant and respected sources of influence for other physicians in their communi¬ ties. Previous research by Coleman et al15 documented that a relatively small proportion of physician leaders are the most integrated into the medical infor¬ mation network and are also the most likely to be extremely influential per¬ suaders of other, less-integrated physi¬ cians. Through these informal social networks, a "contagion" response is seen after adoption by the opinion lead¬ er, aided by the pharmaceutical repre¬ sentatives who may refer to these re¬ spected peers in their own detailing of other practitioners. The involvement of such opinion leaders in the design and implementation of quality of care or cost-containment educational interven¬ tions can also increase their effective¬ ness. Stross and Bole30 observed that surveys of community physicians could easily identify the most educationally influential physicians. These individ¬ uals were subsequently enlisted in a program to upgrade their colleagues' arthritis treatment decisions during in¬ formal "teachable moments," when their advice was being sought on related clinical problems.
Two-Sided Communication
Research has also shown that "inocu¬ lation against counterarguments," or presenting both sides of an issue, aids learning, particularly in situations where the receiver is knowledgeable about counterarguments.31 If detailers completely discount the positive attri¬ butes of an alternative product or thera-peutic approach, their credibility may be damaged and physicians may even feel offended that their beliefs and expe¬ riences were treated as invalid. In¬ stead, the detailer is likely to briefly acknowledge the physician's reasons for using the competitive drug, often elicit¬ ed by asking him. However, he will then deemphasize them in comparison with the advantages of his company's prod¬ uct. For the same reason, the detailer may briefly mention the disadvantages of the drug he is promoting-a message probably communicated already by the competition in any case. The same prin¬ ciple applies to nonprofit educational ef¬ forts. For example, in our attempts to persuade physicians at an urban teach¬ ing hospital to substitute gentamicin when appropriate for tobramycin, we learned that physicians believed the un¬ substantiated marketing claim that to¬ bramycin was less nephrotoxic than gentamicin. Rather than ignoring this important issue (or waiting for physi¬ cians to bring it up), we actively ac¬ knowledged the controversy and pro¬ vided literature references that sup¬ ported the alternative conclusion of no meaningful difference in nephrotoxicity. This process was accomplished in a tactful manner that did not excessively criticize these misperceptions. Promoting Active Learner Involvement Successful behavior change often is dependent on the ability of the educator to relate the message (or product) to the beliefs, needs, values, and interests of the individual physician. Thus, the at¬ tempt to engage the physician in twoway communication is an important way of building a physician-specific presen¬ tation32 at the same time as it increases the involvement of the physician in the interaction. For example, asking the physician why he or she uses a given drug makes it possible to identify and then target relevant motivations and clinical circumstances as well as to gauge the strength of their beliefs.5 In the commercial setting, this also makes it possible for manufacturers to use de¬ tailers as sources of marketing informa¬ tion, particularly in determining reac¬ tions to products soon after their release to the market.25 However, detailers are careful not to overquestion physicians, as this may lead some physicians to feel that their time is being wasted or, worse yet, that the detailer is trying to test or manipulate them.19 A sales-maximizing version of some of these principles is embodied in an article entitled "Credi¬ bility: The Key to Long-term Success," which appeared in a publication for pharmaceutical sales personnel33: Logical, meaningful questioning is an excel¬ lent way to give you credibility and to get the physician into a pattern of dialogue and a mindset towards responding positively to a closing challenge. Probing will get the physi¬ cian to assimilate the information and require him to actively follow your thought direction. As he answers your questions, his thought will begin to crystallize. Remember, a person does his best listening when he is talking.
Similarly, a long history of research and practice in the field of adult learn¬ ing has suggested that stimulating learner involvement through interac¬ tion achieves a higher likelihood of at¬ taining educational and behavioral ob¬ jectives as well as greater satisfaction.34
Our educational detailers were also trained to ask physicians, during both initial and follow-up visits, how they and their patients reacted to prescribing recommendations. These queries often led to identification of correctable ob¬ stacles. For example, discovering that some physicians used propoxyphene as an analgesic because of a lack of aware¬ ness of its risk/benefit attributes made it possible to tailor educational materi¬ als to target these knowledge deficits.
Repetition and Reinforcement
Repetition of a few major points is another technique often ignored in con¬ ventional continuing education that aids in memory retention and promotes be¬ havior change. 35, 36 In a commercial de¬ tailing visit, a few principal advantages of the product are likely to be repeated several times during the detailing visit; the product name itself is further im¬ printed in the physician's mind through gifts from the manufacturer and adver¬ tisements with product identification. While such approaches can be carried to trivial extremes, there is some value to such mnemonic devices. For example, one "giveaway" we considered (but nev¬ er adopted) for our early study was a free sample kit with the label "The Best Antibiotic Therapy for Viral Upper Respiratory Infections" emblazened over a blister-pack whose unit-dose cells were all empty. Rationale and evi¬ dence for these claims would appear on the back of the package. This principle of concentrating on a small number of important messages is based on an un¬ derstanding that educational inter¬ changes successfully transmit but a few points, no matter how complex the mes¬ sages being sent. This is equally true with physicians, who have a hard enough time keeping up with the clutter ofinformation deluge in a rapidly chang¬ ing medical practice. Attempting to communicate too many or complex mes¬ sages often will fail to achieve retention of the most important points. Graphic support with headlines, diagrams, and photographs is an important compo¬ nent, exposing the physician to visual as well as verbal presentation of the main points.
Feedback of improved behavior with reinforcement is another central compo¬ nent of effective detailing techniques that can be used by noncommercial drug information programs. Reinforcement can occur when physicians discuss their experiences with implementing recom¬ mended changes in prescribing behav¬ ior during follow-up visits. Detailers can verbally encourage and applaud their successes as well as discuss prob¬ lem cases and their resolution (eg, pa¬ tient demand). This principle is corrobo¬ rated by data that suggest that a reinforcement visit was associated with a twofold increase in the change in pre¬ scribing behavior in an educational experiment.7
The commercial detailer may encour¬ age the physician to "try out" the prod¬ uct on his patients and to report back his or her experiences at a subsequent visit, often facilitating this with free samples. If these experiences are positive, fur¬ ther discussion and positive reinforce¬ ment of the product ensue. However, it is easy for such a "case study" approach to cross over into pseudoscience. Some pharmaceutical representatives will pursue this strategy further by inviting the physician to conduct a "study" of the product in his or her own practice by giving several patients the promoted drug to compare with others who are taking alternative treatments. In a de¬ scription ofa day spent with a successful drug representative reported in the receptionists are given gifts to gain ac¬ cess to the physician; physicians are giv¬ en both gifts and free samples of the drug; patients receive both samples and educational pamphlets, also donated by the detailer. One particularly offensive use of incentives was the recent cam¬ paign by Ayerst, New York, NY, to promote use of its brand of ß-blocker by offering physicians "frequent prescriber bonuses" for each patient prescribed the product for whom a small reporting form was completed. These could then be traded in for free air travel in the United States and to the Caribbean.
Brief Graphic Print Materials
Recent comprehensive reviews of studies that evaluate a wide variety of mailed continuing educational materi¬ als, including prescribing guidelines and protocols, drug bulletins, commer¬ cially prepared brochures, and two-sid¬ ed "unadvertisements," have produced little or no evidence supporting their effectiveness in changing practice pat¬ terns when used alone.5,10 Nevertheless, well-illustrated materials that empha¬ size the main clinical recommendations in a straightforward way are important adjuncts to face-to-face education that can be mailed, posted, or inserted in patient charts as well as used as a visual device during detailing visits. Figure 2 gives an example of such an educational pamphlet used at Beth Israel Hospital, Boston, Mass, to reduce incorrect use of the antibiotic cefazolin.20 The front cov¬ er of the monograph supports the pre¬ scribing change message in both head¬ lines and graphics; in addition, the credibility provided by support of hospi-tal experts and references to clinical studies published in respected journals are also presented prominently. It is essential to pilot-test materials with physicians who are similar to those in the planned audience to be certain that the content is actually received as intended. Figure 3 presents the front cover of one of six unadvertisements used in a controlled trial of a face-to-face educa¬ tional program to reduce excessive psychoactive drug use in nursing homes. The headline and photograph promote a gentle touch and "tucking in" of elderly residents at bedtime as an alternative to sedative use. On the reverse side, other practical strategies for promoting sleep are emphasized, such as avoiding day¬ time caffeine and napping, and increas¬ ing exercise and mobility. It also en¬ courages more careful selection and dosing of sedatives if they are used. Thorough references to the literature are included. When such graphically il¬ lustrated data are referred to in face-toface sessions they can provide an inter¬ esting and salient respite from verbal presentations and also involve the prescribing physician in two-way communication.
Offering Practical Alternatives
Behavioral science research in nu¬ merous domains documents that it is far easier to get a subject to relinquish a behavior if an alternative behavior is proposed as a replacement, rather than simple inaction. Thus, it is important to offer the prescriber an alternative to the practice being discouraged-either a more rational medication choice or a nonpharmacologic alternative. Phar¬ maceutical representatives ensure that local pharmacies stock the alternative drug recommended to replace specific products prescribed by physicians. Sim¬ ilarly, it is important that academic de¬ tailing programs consider the practical¬ ity and availability of other treatments to replace targeted drug therapies. Nondrug alternative behaviors, in par¬ ticular, may be more difficult to achieve if they require more time to implement. Unfortunately, it may be easier and more convenient for the busy physician to prescribe a benzodiazepine than to engage in a counseling session concern¬ ing the patient's family problems. On the other hand, encouraging patients with peripheral vascular insufficiency to take short walks was a reasonably actionable alternative to use of "periph¬ eral vasodilators" prescribed for this condition.4 To help facilitate this behav¬ ior, a patient education pamphlet was prepared as a physician "prescription" of a specific exercise program, which could be tailored to the patient's physi¬ cal condition (Fig 1) . For this approach to be most effective, there should be no financial disincentives to the patient that act to discourage alternative treat¬ ments. For example, overuse of expen¬ sive prescription analgesics may be dif¬ ficult to reduce in a Medicaid program that does not reimburse for recom¬ mended over-the-counter alternatives such as aspirin or acetaminophen. Selection and Training of Academic Detailers According to the pharmaceutical marketing literature, commercial detail people are selected on the basis of both science background and potential for sales,'* although in practice the latter factor often predominates. There is no standard requirement for any science background, and often none exists. Training is a crucial element in success¬ ful pharmaceutical marketing; it is also the most carefully guarded. Hemminki and Pesonen,14 in a survey of pharma¬ ceutical representatives in Europe, re¬ ported that the mean length of training time before commencing detail work was 14.3 weeks. This was divided be¬ tween sales techniques and a segment on basic medical sciences and pharma¬ cology. Closed-circuit television and role playing are common elements of training used to perfect presentation styles. In addition, fledgling represen¬ tatives may spend some time trying out their presentations on groups of physi¬ cians. This approach is particularly use¬ ful in increasing the representative's ability to answer questions convincingly and to tailor the presentation to the par-ticular style of the physician. Fair trade and advertising laws are emphasized as they apply to the presentations. Management control and feedback to detail people are carried out principally by district sales managers on the basis of ongoing communications from detail¬ ers, including information contained in required call reports as well as reports of sales from pharmacies and in hospi¬ tals.38 Since representatives are gener¬ ally responsible for product sales in par¬ ticular geographic regions, companies can track the amount of a given medica¬ tion sold in those areas to monitor repre¬ sentatives' sales performance. The sales manager is also the key person in providing emotional support to detail people. Although most representatives are salaried, the majority also receive incentives for greater sales through commissions and bonuses.
Based on reports in the medical mar¬ keting literature,13 most pharmaceutical sales representatives probably make between three and eight physician con¬ tacts per day. The contact time per visit varies enormously, but an average of 5 to 8 minutes is a reasonable estimate of average physician exposure time. 13, 19 Because of this limited time, most rep¬ resentatives rarely attempt to promote more than two or, at most, three prod¬ ucts during one visit. One product usu¬ ally represents the major topic to which most of the representative's time is committed during the visit, with a sec¬ ondary drug covered "on the way out the door."
In noncommercial community pro¬ grams, studies have documented the ef¬ fectiveness of clinical pharmacists both with4 and without39 doctoral-level train¬ ing as well as consultant physicians.9
Both pharmacists and specially trained physicians (eg, infectious disease spe¬ cialists) have been used in hospitals5; more study is needed, however, on the comparative cost-effectiveness of vari¬ ous personnel for particular problem ar¬ eas. Doctoral-level clinical pharmacists who were primarily junior faculty in schools of pharmacy have been shown to be effective as part-time, academically based detailers.4"7 Because of their pre¬ vious training in pharmacology and drug information, only about 2 days of formal training was necessary for a pro¬ gram targeting three drugs. This fol¬ lowed self-study of a training manual covering important clinical issues, im¬ portant principles of communication and persuasion, and major recommen¬ dations concerning the target drugs and their alternatives. In the training, vid¬ eotapes were shown of a former phar¬ maceutical representative detailing the target drugs and their alternatives to a physician-researcher (J.A.) who se¬ quentially acted the role of a resistant and hostile physician, an indifferent physician, and a receptive physician.
Following this, approximately a half day was spent practicing on one anoth¬ er, with videotaped feedback. When the pharmacist-educators and investiga¬ tors were satisfied that all trainees were performing adequately, they pretested their presentation on randomly selected community physicians. These encoun¬ ters were discussed by telephone with the project manager before actual de¬ tailing of study physicians began. In general, these initial experiences indi¬ cated that physicians were more recep¬ tive than was expected based on the experiences of commercial represent¬ atives.
After every physician visit, detailed encounter forms were completed to as¬ sess physician receptivity, problems en¬ countered, methods of overcoming ob¬ stacles, call records, exposure times, etc. These were reviewed periodically by the project director (S.B.S.) to at¬ tempt to correct particularly difficult problems experienced by some detail¬ ers. We found that the clinical pharma¬ cists needed only a minimal amount of training and supervision to perform ad¬ equately in this function. This success was evidenced by the prescribing data outcomes: physicians reduced target drug use by 14% compared with controls after only two brief visits (P = .001).4 This is particularly important at a time when powerful new agents are available that have real toxic potential as well as unique therapeutic effectiveness (eg, isotretinoin). Regulation can ensure that drugs with unacceptable risk/bene¬ fit relationships are not permitted to be used, but no current regulatory appara¬ tus can ensure that marketed drugs are prescribed intelligently. It should be possible to take the best of these educa¬ tional approaches and put them at the service of optimal care, while leaving behind any techniques that are not in keeping with the spirit of professionally based continuing medical education.
For example, one important structur-al aspect of the commercial setting, but not generally used in the not-for-profit setting, is the provision of financial in¬ centives that reward pharmaceutical representatives who achieve major pre¬ scribing changes that result in high sales of their company's products (For¬ Human Services and is intended to im¬ prove the use and outcomes of common medical practices nationwide. If such guidelines are not well integrated into formal and informal person-to-person educational programs they may not have any practical value. In coming years, it is likely that computer-based decision support systems will become sophisticated and widespread enough that some (but not all) of the interac¬ tions described above will be done elec¬ tronically. However, such capacity is not likely to be available in most prac¬ tice settings in the immediate future.
Some may argue that restrictions and regulations, rather than education, are simpler and more effective strategies for improving prescribing practice. In fact, restrictive hospital formularies are an effective means of reducing improper use of some medications. However, for many medications the problem is mis¬ use of an otherwise effective agent (eg, antibiotics). Removing access to the drug through a restrictive formulary or reimbursement restrictions cannot ad¬ dress this issue. Further, drug restric¬ tions are not practical without effective sanctions and enforcement. In addition, no extensive literature exists on the ef-fectiveness of drug restrictions in com¬ munity settings, and the few extant studies suggest that restrictions of one drug can lead to generally inappropriate use of substitute medications.5,45 Educa¬ tional approaches thus are more flexible and adaptable in influencing most realworld clinical decisions that do not fall into neatly defined categories of correct and incorrect practice.
The cost of new therapies is increas¬ ing sharply at the same time that pres¬ sure is escalating to control health care costs. A small but important body of research and practice has begun to emerge based on the concept of academ¬ ic detailing that may present a rational response to these pressures. Such edu¬ cational outreach activities by universi¬ ties, medical centers, and professional associations are increasingly proposed or being implemented under the spon¬ sorship of hospitals, public-sector programs, health maintenance organi¬ zations, and other insurers. The appli¬ cability of this approach offers promise to other areas beyond prescribing, such as the use of blood products, laboratory tests, and other diagnostic resources and the decision to hospitalize. In this way, improved precision in clinical deci¬ sion making can present an attractive alternative to the twin extremes of un¬ acceptable costs and unacceptable restriction.
